BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.

Cat No.	product name
T10626	(Rac)-IBT6A	(Rac)-IBT6A 是 IBT6A 的外消旋体。 IBT6A 是依鲁替尼的杂质，可用于 IBT6A 依鲁替尼二聚体和 IBT6A 加合物的合成。
T2472	CGI-1746	CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
T4391	Syk Inhibitor II (hydrochloride)	Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chain...
T9705	TL-895	TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and...
T6078	Saracatinib	Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T6217	LFM-A13	LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and...
T9706	BTK inhibitor 17	BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.
T4337	PCI 29732	PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
T16157	MT-802	MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
T6921	ONO-4059 analog	ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
T12542	Rilzabrutinib	PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T9072	Tuxobertinib	BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reape...
T13564	AZ7550	AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
T35330	BTK inhibitor 1 (Compound 27)	BTK inhibitor 1 (compound 27) is an inhibitor ofBTKwith an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.
T9408	N-piperidine Ibrutinib	N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively[1]. N-piperidine Ibrutinib can be used as a...
T1835	Ibrutinib	Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T1976	RN486	RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
T2603	Spebrutinib	Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
T2302	CNX-774	CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
T7584	Zanubrutinib	Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
T9192	BIIB068	BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
T9125	Tolebrutinib	Tolebrutinib is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC...
T8636	Ibrutinib deacryloylpiperidine	Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
T10625	IBT6A	IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T10629	Btk inhibitor 2	Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
T10240	ACP-5862	ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
T11379	GDC-0834	GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and r...
T12152	N-piperidine Ibrutinib hydrochloride	N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
T12317	Orelabrutinib	Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
T12311	Tirabrutinib hydrochloride	Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
T12673L	PF-06250112	PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
TQ0242	Fenebrutinib	Fenebrutinib is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
TQ0230	BTK IN-1	BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
TQ0236	Tirabrutinib	Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
TQ0039	(±)-Zanubrutinib	(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
T6918	Olmutinib	Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. ...
T3626	Acalabrutinib	Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administrat...
T3024	Avitinib	Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potent...
T4268	CHMFL-BMX-078	CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
T5407	Branebrutinib	BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK...
T5138	BMS-986142	BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
T14323	ARQ 531	ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectiv...
T14357	Spebrutinib besylate	Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T15365	G-744	G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
T14956	CHMFL-BTK-01	CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T14692	BMX-IN-1	BMX-IN-1 是 X 染色体上的骨髓酪氨酸激酶 (BMX, IC50 = 8 nM) 和相关的布鲁顿酪氨酸激酶 (BTK, IC50 = 10.4 nM) 的特异性抑制剂，但 BMX-IN-1 对 Blk、JAK3、EGFR、Itk 或 Tec 活性的效力要低 47-656 倍以上。
T14681	BMS-935177	BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
T16441	PCI-33380	PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T16265	Naluzotan	Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety...
T17098	Tilfrinib	Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.